^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | DO-1 (c-MET inhibitor, SLC22A2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
Published date:
06/01/2023
Excerpt:
In the expansion cohorts, 15 patients were included (10 in METex14-positive NSCLC cohort and 5 in MET basket cohort) and received either 200 or 250 mg BID. Eight out of the 10 patients with METex14 positive NSCLC had stable disease as the best response.
DOI:
https://doi.org/10.1093/oncolo/oyad146
Trial ID:
